FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3005076504> ?p ?o ?g. }

• W3005076504 endingPage "143" @default.
• W3005076504 startingPage "143" @default.
• W3005076504 abstract "Hagenia abyssinica (Bruce) J. F. Gmel. is a multipurpose dioecious tree that has been used to treat various ailments, for example, the flowers of H. abyssinica have been widely used as a tea to treat intestinal parasites by local residents and the roots of H. abyssinica could also be used for anticancer purposes. Antioxidant activity could be one of the most important pathways to suppress cancer and there is hardly any information available on the specific chemical components corresponding to the bioactivities of H. abyssinica to date. The present study intended to screen and evaluate the antioxidant and anti-proliferative properties of five different fractions from H. abyssinica along with their corresponding total flavonoid and phenolic contents and then further identify those compounds with the most potent antioxidant and anti-proliferative activities using high performance liquid chromatography (HPLC) coupled to mass spectrometry (MS) and nuclear magnetic resonance (NMR). The total flavonoid and phenolic content assays showed that the ethyl acetate (EA) fraction of H. abyssinica had higher flavonoid and phenolic levels than the other four fractions. Furthermore, the 2,2-diphenyl-1-picrylhydrazyl (DPPH) superoxide radical scavenging abilities, total antioxidant capacity (TAC) assay with 2,2′-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid (ABTS), and ferric-reducing antioxidant power (FRAP) were measured to evaluate the antioxidant activities of the five fractions and some pure compounds isolated from the EA fraction, which displayed higher antioxidant properties than that of the other fractions. Caffeic acid from the EA fraction showed even stronger DPPH scavenging ability (IC50 7.858 ± 0.31 µg/mL) than that of Vc (IC50 8.27 ± 0.11 µg/mL) as the positive control. The anti-proliferative properties of four fractions and the ethanol extract were evaluated by the 3-(4,5)-dimethylthiahiazo (-z-y1)-3,5-di-phenytetrazoliumromide (MTT) assay and the EA fraction exhibited higher anti-proliferative activities against three cancer cell lines than that of the other fractions. Additionally, the compounds with good antioxidant activity from the EA fraction of H. abyssinica were screened and identified using LC-MS and NMR and were also found to possess good anti-proliferative activity. In the MTT assay, the quercetin showed the strongest dose-dependent anti-proliferative activities to colon cancer cells (HT-29) and liver cancer cells (HepG2) among all of the compounds isolated. This study provided valuable information on the synergistic antioxidant and anti-proliferative properties of H. abyssinica." @default.
• W3005076504 created "2020-02-14" @default.
• W3005076504 creator A5005359731 @default.
• W3005076504 creator A5012769245 @default.
• W3005076504 creator A5018177737 @default.
• W3005076504 creator A5027734227 @default.
• W3005076504 creator A5044990015 @default.
• W3005076504 creator A5067355359 @default.
• W3005076504 creator A5073116952 @default.
• W3005076504 date "2020-02-06" @default.
• W3005076504 modified "2023-10-07" @default.
• W3005076504 title "Antioxidant and Anti-Proliferative Properties of Hagenia abyssinica Roots and Their Potentially Active Components" @default.
• W3005076504 cites W1604122966 @default.
• W3005076504 cites W1937431942 @default.
• W3005076504 cites W1964008401 @default.
• W3005076504 cites W1967487924 @default.
• W3005076504 cites W1971065441 @default.
• W3005076504 cites W1972779889 @default.
• W3005076504 cites W1973799680 @default.
• W3005076504 cites W1990959547 @default.
• W3005076504 cites W1993238109 @default.
• W3005076504 cites W1996029030 @default.
• W3005076504 cites W1997191564 @default.
• W3005076504 cites W1997430296 @default.
• W3005076504 cites W2000118672 @default.
• W3005076504 cites W2006697833 @default.
• W3005076504 cites W2008049644 @default.
• W3005076504 cites W2012991711 @default.
• W3005076504 cites W2019060471 @default.
• W3005076504 cites W2021112508 @default.
• W3005076504 cites W2022132995 @default.
• W3005076504 cites W2024401892 @default.
• W3005076504 cites W2028175766 @default.
• W3005076504 cites W2034269086 @default.
• W3005076504 cites W2043080981 @default.
• W3005076504 cites W2044302969 @default.
• W3005076504 cites W2044955304 @default.
• W3005076504 cites W2047085216 @default.
• W3005076504 cites W2052735421 @default.
• W3005076504 cites W2064849076 @default.
• W3005076504 cites W2068140333 @default.
• W3005076504 cites W2068919269 @default.
• W3005076504 cites W2068996478 @default.
• W3005076504 cites W2070995184 @default.
• W3005076504 cites W2079183298 @default.
• W3005076504 cites W2079588482 @default.
• W3005076504 cites W2085138191 @default.
• W3005076504 cites W2086959952 @default.
• W3005076504 cites W2089891923 @default.
• W3005076504 cites W2092329172 @default.
• W3005076504 cites W2093373886 @default.
• W3005076504 cites W2093603295 @default.
• W3005076504 cites W2102602516 @default.
• W3005076504 cites W2124435317 @default.
• W3005076504 cites W2136117925 @default.
• W3005076504 cites W2156293254 @default.
• W3005076504 cites W2165292984 @default.
• W3005076504 cites W2168502857 @default.
• W3005076504 cites W2312943325 @default.
• W3005076504 cites W2322442391 @default.
• W3005076504 cites W2499001724 @default.
• W3005076504 cites W2738746147 @default.
• W3005076504 cites W2739901926 @default.
• W3005076504 cites W2805933403 @default.
• W3005076504 cites W2895935947 @default.
• W3005076504 cites W2922606517 @default.
• W3005076504 cites W2940492342 @default.
• W3005076504 cites W2940628258 @default.
• W3005076504 cites W2965792844 @default.
• W3005076504 cites W2967937728 @default.
• W3005076504 cites W3027494665 @default.
• W3005076504 doi "https://doi.org/10.3390/antiox9020143" @default.
• W3005076504 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7070924" @default.
• W3005076504 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32041310" @default.
• W3005076504 hasPublicationYear "2020" @default.
• W3005076504 type Work @default.
• W3005076504 sameAs 3005076504 @default.
• W3005076504 citedByCount "15" @default.
• W3005076504 countsByYear W30050765042020 @default.
• W3005076504 countsByYear W30050765042021 @default.
• W3005076504 countsByYear W30050765042022 @default.
• W3005076504 countsByYear W30050765042023 @default.
• W3005076504 crossrefType "journal-article" @default.
• W3005076504 hasAuthorship W3005076504A5005359731 @default.
• W3005076504 hasAuthorship W3005076504A5012769245 @default.
• W3005076504 hasAuthorship W3005076504A5018177737 @default.
• W3005076504 hasAuthorship W3005076504A5027734227 @default.
• W3005076504 hasAuthorship W3005076504A5044990015 @default.
• W3005076504 hasAuthorship W3005076504A5067355359 @default.
• W3005076504 hasAuthorship W3005076504A5073116952 @default.
• W3005076504 hasBestOaLocation W30050765041 @default.
• W3005076504 hasConcept C185592680 @default.
• W3005076504 hasConcept C2778004101 @default.
• W3005076504 hasConcept C2778224086 @default.
• W3005076504 hasConcept C2779054382 @default.
• W3005076504 hasConcept C2779858419 @default.
• W3005076504 hasConcept C2781031786 @default.
• W3005076504 hasConcept C2781401929 @default.

• next